Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Meir intratympanic dexamethasone cisplatin-otoprotection study

Also known as: Intratympanic dexamethasone for cisplatin ototoxicity, NCT01372904

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Steroid/Anti-inflammatory

Stage

Phase 4

Status

Completed

Target Gene

—

Route / Mode

Intratympanic injection

Confidence

76%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Israel

Population

adult, cisplatin-ototoxicity, study-level

Trial IDs

Mechanism

Completed hospital-led Phase 4 prevention study of unilateral intratympanic dexamethasone phosphate injection before cisplatin exposure to assess protection from cisplatin-associated sensorineural hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss Cisplatin-Induced Hearing Loss

Notes

Split out from the broad dexamethasone cluster. ClinicalTrials.gov verifies a completed Meir Medical Center Phase 4 intratympanic dexamethasone study for cisplatin ototoxicity prevention; this is a generic steroid study, not a proprietary otoprotective product.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT01372904

Open

Key Events

2011-06-01

Registry-listed start of intratympanic dexamethasone cisplatin-otoprotection study

2013-06-01

Registry-listed actual completion of cisplatin-otoprotection study

Clinical Trials (1)